

This is a repository copy of *Towards evidence based medicine for paediatricians*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/121690/>

Version: Published Version

Article:

Phillips, Bob orcid.org/0000-0002-4938-9673 (2017) Towards evidence based medicine for paediatricians. *Archives of Disease in Childhood*. p. 780. ISSN: 1468-2044

<https://doi.org/10.1136/archdischild-2017-313580>

Reuse

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Towards evidence based medicine for paediatricians

Edited by Bob Phillips

Can our children's trials work better than they do?

We're all well aware of the problems of doing randomised clinical trials in paediatrics but are we as aware of some alternative approaches that have been used?¹

'Sequential design' studies look at comparing a series of treatments against each other, switching to the 'better' arm and comparing against the next candidate as time progresses. They need quickly and easily available outcomes and tend to be usable only for short-course treatments but they've been estimated to reduce sample sizes by about 25%.

'Adaptive design' begins by pitting all the contenders against each other and dropping off the weakest. It can then roll onwards with the final two into a more 'traditional' trial design. Again, this needs pretty rapid outcomes and fairly short-course treatments, but reduces numbers to only half of those needed in repeated traditional design trials.

'Response adapted' designs are intriguing. These include the withdrawal-enriched design—where everyone gets the treatment to start with, then those who show response are randomised to having placebo or carrying on with therapy. This is tricky with ethics—if you've shown it to work can you stop?—and has the risk of carryover effects, and doesn't work for curative treatments. Another variation is the three-stage design, which starts with a randomisation to treatment/placebo. Stage 2 is taking the non-responders to placebo, and randomising those again to placebo/treatment, and stage 3, where only those who have responded to treatment are taken and randomised to placebo/carry-on (like the withdrawal design). This works well with chronic conditions where therapy is not disease modifying, but changes outcomes for a short period.

'Placebo-phase' randomisations are appealing for therapies with a good chance of success. These randomise participants to all receive the treatment ... the randomisation is about 'when' to get it ... with variable placebo phases before treatment is commenced. This offers the opportunity to treat every child, and still manage to estimate the effect of a therapy. This does rely on (a) you not requiring immediate disease-altering treatment and (b) the disease process not changing massively over time so the 'later' ones have more disease to get rid of than the earlier ones.

'Bayesian approaches' are the oddest to think about. They start from the principle that we do *not* have a 50% knowledge about a therapy, but based on adult evidence and possibly prior phase II child studies, we actually believe it's about 60%–70% (or whatever) effective. The trial analysis then 'builds' on this 'prior knowledge' to come up with an answer based on the assumptions and the data. This can greatly reduce the amount of people needed in the trial, but can feel very suspect.

Bob Phillips

Correspondence to Dr Bob Phillips, University of York, Centre for Reviews and Dissemination, York YO10 5DD, UK; bob.phillips@doctors.org.uk

Competing interests None declared.

Provenance and peer review Commissioned; internally peer reviewed.

Received 20 June 2017

Accepted 21 June 2017



- <http://dx.doi.org/10.1136/archdischild-2017-313107>
- <http://dx.doi.org/10.1136/archdischild-2017-313242>

Arch Dis Child 2017;**102**:780. doi:10.1136/archdischild-2017-313580

REFERENCE

- 1 Baiardi P, Giaquinto C, Girotto S, *et al*. TEDDY Network of Excellence. innovative study design for paediatric clinical trials. *Eur J Clin Pharmacol* 2011;67(Suppl 1):109–15.





Towards evidence based medicine for paediatricians

Bob Phillips

Arch Dis Child 2017 102: 780

doi: 10.1136/archdischild-2017-313580

Updated information and services can be found at:
<http://adc.bmj.com/content/102/8/780.2>

These include:

References

This article cites 1 articles, 0 of which you can access for free at:
<http://adc.bmj.com/content/102/8/780.2#BIBL>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections
[ADC Archimedes](#) (268)

Notes

To request permissions go to:
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:
<http://group.bmj.com/subscribe/>